^
    2d
    A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=71, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK positive • ALK fusion • ROS1 fusion • ROS1 positive
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
    |
    Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib)
    2d
    Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer (clinicaltrials.gov)
    P2, N=23, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Dec 2025 --> Apr 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    paclitaxel • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide
    2d
    MDS: Pacritinib With Aza for Upfront Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=25, Not yet recruiting, Thomas Jefferson University
    New P1/2 trial
    |
    azacitidine • Vonjo (pacritinib)
    6d
    A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA) (clinicaltrials.gov)
    P4, N=15, Active, not recruiting, University of Alabama at Birmingham | Recruiting --> Active, not recruiting
    Enrollment closed
    6d
    NCI-2020-01626: Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis (clinicaltrials.gov)
    P2, N=79, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | N=60 --> 79 | Trial completion date: Dec 2029 --> Apr 2030
    Enrollment closed • Enrollment change • Trial completion date
    |
    Jakafi (ruxolitinib) • cyclophosphamide • methotrexate • melphalan • fludarabine IV • busulfan
    7d
    A clinical study of ruxolitinib combined with reduced-dose HLH-1994 regimen in the treatment of adult hemophagocytic lymphohistiocytosis (ChiCTR2500115370)
    P=N/A, N=20, Not yet recruiting, Shandong Provincial Qianfoshan Hospital; Shandong Provincial Qianfoshan Hospital
    New trial
    |
    Jakafi (ruxolitinib)
    7d
    A real-world study on the influencing factors of the efficacy of ruxolitinib cream in the treatment of vitiligo (ChiCTR2500115141)
    P=N/A, N=170, Not yet recruiting, Peking University Third Hospital; Peking University Third Hospital
    New trial
    7d
    Clinical study on the safety and efficacy of gecacitinib hydrochloride tablets in the treatment of mild to moderate acute graft-versus-host disease (ChiCTR2500113066)
    P=N/A, N=15, Not yet recruiting, Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital
    New trial
    7d
    A Clinical Study on the Efficacy and Safety of JAK/ACVR1 Inhibitors in the Treatment of Steroid-resistant Chronic Graft-versus-Host Disease (ChiCTR2500112276)
    P=N/A, N=40, Not yet recruiting, The Second Affiliated Hospital of the Army Medical University; The Second Affiliated Hospital of the Army Medical University
    New trial
    7d
    Real-world study of The efficacy and safety of The JAK inhibitor Baricitinib and Ritlecitinib for the treatment of severe alopecia areata (ChiCTR2500114501)
    P=N/A, N=150, Completed, The FIrst Affiliated Hospital, College of Medicine, Zhejiang University; The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
    New trial
    |
    Litfulo (ritlecitinib)
    7d
    A Clinical Study on the Safety and Efficacy of Gecacitinib Hydrochloride Tablets in the Treatment of Myelodysplastic Syndromes (MDS) and Myelodysplastic Syndromes/Myeloproliferative Neoplasm （MDS/MPN）Patients with Anemia. (ChiCTR2500113178)
    P4, N=48, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College.; Institute of Hematolog
    New P4 trial
    7d
    A randomized, double-blind, excipi-controlled, multicenter Phase III clinical study to evaluate the efficacy and safety of ruxolitinib gel (HDM3010) in adult subjects with mild to moderate pruritus nodules (ChiCTR2600117276)
    P3, N=360, Not yet recruiting, Hangzhou First People's Hospital; Hangzhou First People's Hospital
    New P3 trial
    |
    Jakafi (ruxolitinib)